SCHEMBL6451341

SCHEMBL6451341

COc1ccc(-c2ccc(C(F)(F)C=O)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
CYP2A6 P11509 1/20 0.45
ESR2 Q92731 1/20 0.45
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1B1 Q16678 1/20 0.42
MAOB P27338 1/20 0.42
HSD11B1 P28845 1/20 0.41
ERN1 O75460 1/20 0.41
PGR P06401 1/20 0.41
AR P10275 1/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20325786 0.94 ALDH1A1 (0.50) ALDH1A1CYP2A6CA12CA1CA2
SCHEMBL3992142 0.79 KIF11 (0.54) ESR2CA12CA1CA2CA7
SCHEMBL16147100 0.76 ABL1 (0.47) NPC1RAB9AMAOBTP53SMN1; SMN2
SCHEMBL13211691 0.74 ESR2 (0.56) ALDH1A1ESR2CA12CA1CA2
SCHEMBL6450429 0.74 PTGDR2 (0.51) ESR2CA1CA2NPC1RAB9A
SCHEMBL16147603 0.74 NPSR1 (0.44) ALDH1A1CA1CA2CA7CA9
SCHEMBL9151672 0.73 CA1 (0.79) ALDH1A1ESR2CA12CA1CA2
SCHEMBL6733562 0.73 CA1 (0.79) ALDH1A1ESR2CA12CA1CA2
SCHEMBL197522 0.73 CA1 (0.79) ALDH1A1ESR2CA12CA1CA2
SCHEMBL7931650 0.73 HSD11B1 (0.49) ALDH1A1CYP2A6CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852751-B2 Difluorobutyric acid metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-02-08 US disclosed
US-20030139453-A1 Difluorobutyric acid metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-07-24 US disclosed
EP-1265865-A2 DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-12-18 EP disclosed
WO-2001070693-A2 DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139453-A1 Difluorobutyric acid metalloprotease inhibitors DPEP1, TMPRSS15, FAP ALDH1A1 251/4885CYP2A6 605/4885ESR2 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.